MX336214B - Derivados de pirrolotriazinona como inhibidores de pi3k. - Google Patents

Derivados de pirrolotriazinona como inhibidores de pi3k.

Info

Publication number
MX336214B
MX336214B MX2013011781A MX2013011781A MX336214B MX 336214 B MX336214 B MX 336214B MX 2013011781 A MX2013011781 A MX 2013011781A MX 2013011781 A MX2013011781 A MX 2013011781A MX 336214 B MX336214 B MX 336214B
Authority
MX
Mexico
Prior art keywords
pi3k inhibitors
pyrrolotriazinone derivatives
pyrrolotriazinone
derivatives
inhibitors
Prior art date
Application number
MX2013011781A
Other languages
English (en)
Other versions
MX2013011781A (es
Inventor
Ferrer Jordi Gracia
Anchuela Francisco Javier Bernal
Riera Marta Carrascal
Javaloyes Juan Francisco Caturla
Víctor Giulio Matassa
Belart Emma Terricabras
Moll Joan Taltavull
Sola Montserrat Erra
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2013011781A publication Critical patent/MX2013011781A/es
Publication of MX336214B publication Critical patent/MX336214B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

(Ver Formula) Se describen nuevos derivados de pirrolotriazinona que tienen la estructura química de fórmula (I); así como un procedimiento para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia como inhibidores de Fosfoinositido 3-quinasas (PI3Ks).
MX2013011781A 2011-04-29 2012-04-26 Derivados de pirrolotriazinona como inhibidores de pi3k. MX336214B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382124A EP2518070A1 (en) 2011-04-29 2011-04-29 Pyrrolotriazinone derivatives as PI3K inhibitors
US201161502550P 2011-06-29 2011-06-29
PCT/EP2012/057671 WO2012146666A1 (en) 2011-04-29 2012-04-26 Pyrrolotriazinone derivatives as pi3k inhibitors

Publications (2)

Publication Number Publication Date
MX2013011781A MX2013011781A (es) 2013-11-01
MX336214B true MX336214B (es) 2016-01-12

Family

ID=44484054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011781A MX336214B (es) 2011-04-29 2012-04-26 Derivados de pirrolotriazinona como inhibidores de pi3k.

Country Status (36)

Country Link
US (1) US9340547B2 (es)
EP (2) EP2518070A1 (es)
JP (1) JP5903160B2 (es)
KR (1) KR20140021622A (es)
CN (1) CN103649089B (es)
AR (1) AR086144A1 (es)
AU (1) AU2012247491B2 (es)
BR (1) BR112013023876A2 (es)
CA (1) CA2826197A1 (es)
CL (1) CL2013003073A1 (es)
CO (1) CO6801747A2 (es)
CR (1) CR20130543A (es)
CY (1) CY1116871T1 (es)
DK (1) DK2702061T3 (es)
EA (1) EA024350B1 (es)
ES (1) ES2545853T3 (es)
GT (1) GT201300266A (es)
HK (1) HK1195552A1 (es)
HR (1) HRP20151153T1 (es)
HU (1) HUE026041T2 (es)
IL (1) IL227764A (es)
ME (1) ME02210B (es)
MX (1) MX336214B (es)
MY (1) MY171553A (es)
PE (1) PE20141193A1 (es)
PL (1) PL2702061T3 (es)
PT (1) PT2702061E (es)
RS (1) RS54270B1 (es)
SG (1) SG194084A1 (es)
SI (1) SI2702061T1 (es)
SM (1) SMT201500270B (es)
TW (2) TWI535720B (es)
UA (1) UA111197C2 (es)
UY (1) UY34051A (es)
WO (1) WO2012146666A1 (es)
ZA (1) ZA201305612B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
SG11201502032VA (en) * 2012-10-16 2015-05-28 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
MX2015006192A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
WO2014082230A1 (zh) * 2012-11-28 2014-06-05 上海希迈医药科技有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) * 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
AR094797A1 (es) * 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
JP6030783B2 (ja) 2013-06-14 2016-11-24 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
WO2015023776A2 (en) * 2013-08-13 2015-02-19 The Regents Of The University Of California Deoxycytidine kinase inhibitors
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
PL3129021T3 (pl) * 2014-04-08 2021-05-31 Incyte Corporation Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k
MA39827A (fr) * 2014-05-27 2015-12-03 Almirall Sa Sels d'addition de (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)éthyl)-4-oxo-3-phényl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
ES2763104T3 (es) 2014-06-13 2020-05-27 Gilead Sciences Inc Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-quinasa
CA2952044C (en) * 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
SG11201610770PA (en) 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
ES2879809T3 (es) 2014-11-01 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de proteínas quinasas
US10301292B2 (en) 2014-11-26 2019-05-28 Takeda Pharmaceutical Company Limited Bicyclic compound
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3672597A4 (en) * 2017-08-21 2021-09-22 Navigen, Inc. ARF6 INHIBITORS AND RELATED PROCEDURES
MA50256A (fr) * 2017-09-15 2020-07-22 Aduro Biotech Inc Composés de pyrazolopyrimidinone et leurs utilisations
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2019281888B2 (en) 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
US20210269447A1 (en) * 2018-07-06 2021-09-02 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
US20220289751A1 (en) * 2019-07-17 2022-09-15 Ono Pharmaceutical Co., Ltd. Compound having kdm5 inhibitory activity and pharmaceutical use thereof
CN111346095B (zh) * 2020-03-14 2021-06-08 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗神经外科术后头痛的药物制剂
WO2021233227A1 (en) * 2020-05-16 2021-11-25 Fochon Pharmaceuticals, Ltd. Compounds as protein kinase inhibitors
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
US5200416A (en) * 1980-05-12 1993-04-06 Usv Pharmaceutical Corporation Cyclic amides
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE164525T1 (de) 1990-09-26 1998-04-15 Pharmachemie Bv Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
RU2111020C1 (ru) 1992-12-18 1998-05-20 Шеринг Корпорейшн Ингалятор для порошковых лекарств
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
IL122494A (en) 1995-06-21 2001-08-08 Asta Medica Ag A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2004289518A1 (en) 2003-11-10 2005-05-26 Merck Sharp & Dohme Limited Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR101214823B1 (ko) 2004-07-16 2012-12-24 알미랄, 에스.에이. 분말 약제의 투약을 위한 흡입기 및 이 흡입기와 함께사용하기 위한 분말 카트리지 시스템
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ZA200801822B (en) * 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2411391A1 (en) * 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Also Published As

Publication number Publication date
WO2012146666A1 (en) 2012-11-01
BR112013023876A2 (pt) 2016-12-13
EA201301209A1 (ru) 2014-04-30
JP5903160B2 (ja) 2016-04-13
HUE026041T2 (en) 2016-05-30
EA024350B1 (ru) 2016-09-30
GT201300266A (es) 2015-04-06
NZ614082A (en) 2015-05-29
AR086144A1 (es) 2013-11-20
CA2826197A1 (en) 2012-11-01
HRP20151153T1 (hr) 2015-12-04
UY34051A (es) 2012-11-30
TWI535720B (zh) 2016-06-01
MY171553A (en) 2019-10-18
PT2702061E (pt) 2015-10-26
IL227764A0 (en) 2013-09-30
TW201247674A (en) 2012-12-01
PL2702061T3 (pl) 2016-01-29
KR20140021622A (ko) 2014-02-20
TW201242967A (en) 2012-11-01
EP2518070A1 (en) 2012-10-31
US20140163033A1 (en) 2014-06-12
MX2013011781A (es) 2013-11-01
CN103649089A (zh) 2014-03-19
AU2012247491B2 (en) 2016-08-18
CL2013003073A1 (es) 2014-02-21
SMT201500270B (it) 2016-01-08
ZA201305612B (en) 2014-05-28
SG194084A1 (en) 2013-11-29
ES2545853T3 (es) 2015-09-16
UA111197C2 (uk) 2016-04-11
DK2702061T3 (en) 2015-11-09
JP2014515027A (ja) 2014-06-26
SI2702061T1 (sl) 2016-01-29
EP2702061B9 (en) 2016-02-24
HK1195552A1 (en) 2014-11-14
CR20130543A (es) 2014-03-17
CN103649089B (zh) 2016-06-29
ME02210B (me) 2016-02-20
EP2702061B1 (en) 2015-07-29
US9340547B2 (en) 2016-05-17
CY1116871T1 (el) 2017-04-05
PE20141193A1 (es) 2014-09-03
IL227764A (en) 2016-07-31
RS54270B1 (en) 2016-02-29
CO6801747A2 (es) 2013-11-29
US20150099752A9 (en) 2015-04-09
EP2702061A1 (en) 2014-03-05
AU2012247491A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
PH12015500813B1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX2012007175A (es) Derivados de imidazopiridina como inhibidores de jak.
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX336381B (es) Boronatos como inhibidores de arginasa.
MD20140002A2 (ro) Indazoli
NZ708870A (en) Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
MY177344A (en) Compounds and their methods of use
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX2014000635A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
WO2012104007A3 (de) 7-azaindolderivate
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao